Market: NASD |
Currency: USD
Address: Building 7
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
📈 Chemomab Therapeutics Ltd. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$32.00
-
Upside/Downside from Analyst Target:
819.54%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2021 |
- |
$0.062500 |
- |
2021-03-17 |
- |
Stock split |
|
Total Amount for 2021: $0.062500 |
📅 Earnings & EPS History for Chemomab Therapeutics Ltd.
| Date | Reported EPS |
|---|
| 2025-08-14 | -0.02 |
| 2025-05-15 | -0.03 |
| 2025-03-03 | -0.03 |
| 2024-11-14 | -0.04 |
| 2024-08-21 | 0.05 |
| 2024-05-09 | -0.06 |
| 2024-03-07 | -0.05 |
| 2023-11-09 | -0.07 |
| 2023-08-14 | -0.14 |
| 2023-05-11 | -0.16 |
| 2023-02-21 | -0.14 |
| 2022-11-10 | -0.14 |
| 2022-08-12 | -0.11 |
| 2022-05-12 | -0.09 |
| 2022-03-09 | -0.09 |
| 2021-11-12 | -0.05 |
| 2021-08-13 | -0.05 |
| 2021-05-13 | -0.04 |
📰 Related News & Research
No related articles found for "chemomab therapeutics".
